Utilization of Magee equation 3 in ER-positive, HER2-negative/equivocal tumors to determine pathologic response to neoadjuvant therapy.

Authors:

Abstract
11594 Background: Magee Equations (ME) were derived to estimate Oncotype DX scores (Mod Pathol. 2013;26:658-64). ME3 uses only the immunohistochemical/FISH data for ER, PR, HER2 and Ki-67 for calculation (24.30812+ERIHC*(−0.02177)+PRIHC*(−0.02884)+(0 for HER2-ve, 1.46495 for equivocal, 12.75525 for HER2+ve)+Ki-67*0.18649). We hypothesized that ME3 scores from pre-therapy core biopsy can be used to predict response to NAT. Methods: A retrospective chart review was conducted of patients who received NAT from 2010-2014 at a single institution. Of 595 patients that had tumor ER status, HER2 status and pathologic complete response (pCR) information available, we excluded 359 tumors that were ER -ve or showed unequivocal HER2 gene amplification. pCR was defined as absence of invasive tumor in the breast and regional lymph nodes (LN). ME3 scores were grouped into 3 categories similar to Oncotype DX, i.e. 0 to <18, 18 to <31, and ≥31. Univariate analyses were performed using Fisher exact test. Results: 236 ER+, HER2 -ve/equivocal tumors were eligible for consideration. Mean followup was 33.3 months. Table 1 shows that pCR rate increases with higher ME3 score categories (RR 27 for ME3 ≥31 vs <18). For patients that do not achieve pCR, ME3 score ≥31 correlates with increased risk of overall recurrence, with the majority occurring in patients with +ve LN in the resection specimen (Table 2). Conclusions: ME3 score ≥31 predicts for pCR in the neoadjuvant setting and paradoxically for tumor recurrence when pCR is not achieved. These results validate the use of ME3 in selecting patients who will benefit from chemotherapy but require validation outside a single institution.